Jove
Visualize
Contact Us

Related Experiment Videos

[Raloxifene in postmenopausal women].

F Trémollières1, C Ribot

  • 1UF Ménopause et Maladies Osseuses Métaboliques, Hôpital Paule-de-Viguier, 330, avenue de Grande-Bretagne, 31059 Toulouse cedex 09, France. tremollieres.f@chu-toulouse.fr

Gynecologie, Obstetrique & Fertilite
|February 18, 2006
PubMed
Summary

Raloxifene effectively prevents postmenopausal bone loss and vertebral fractures, offering an alternative to hormone therapy. It has potential extraskeletal benefits but may not alleviate menopausal symptoms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of women with abnormal uterine bleeding: Clinical practice guidelines of the French National College of Gynaecologists and Obstetricians (CNGOF).

European journal of obstetrics, gynecology, and reproductive biology·2023
Same author

[Women with a very high risk of breast cancer: Contraceptives, hormonal replacement therapy use and personalized screening].

Gynecologie, obstetrique, fertilite & senologie·2023
Same author

Quality of life of patients with bilateral oophorectomy before the age of 45 for the treatment of endometriosis.

Maturitas·2022
Same author

[Management of women with abnormal uterine bleeding: Clinical practice guidelines of the French National College of Gynecologists and Obstetricians (CNGOF)].

Gynecologie, obstetrique, fertilite & senologie·2022
Same author

[Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines (Short version)].

Gynecologie, obstetrique, fertilite & senologie·2021
Same author

[Menopause hormone treatment in practice. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines].

Gynecologie, obstetrique, fertilite & senologie·2021
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Endocrinology
  • Pharmacology
  • Bone Biology

Context:

  • Postmenopausal hormone therapy (HT) use has declined due to safety concerns, shifting osteoporosis prevention strategies.
  • Selective estrogen receptor modulators (SERMs) like raloxifene offer tissue-specific effects, acting as estrogen agonists on bone and antagonists on other tissues.

Purpose:

  • To evaluate the efficacy and safety of raloxifene for osteoporosis prevention in postmenopausal women.
  • To assess the extraskeletal benefits and potential limitations of raloxifene in managing postmenopausal health.

Summary:

  • Raloxifene demonstrated significant efficacy in inhibiting postmenopausal bone loss and reducing vertebral fracture incidence in a large trial (MORE).
  • Its estrogen antagonist effects on breast tissue and favorable safety profile regarding endometrium and cardiovascular health are notable.

Related Experiment Videos

  • Adverse events include a comparable risk of venous thromboembolism as HT; efficacy for menopausal symptoms like hot flashes is limited.

    • Impact:

    • Raloxifene provides a valuable therapeutic option for osteoporosis prevention in postmenopausal women, particularly those at high risk.
    • Its extraskeletal effects and safety profile may extend its utility beyond bone health, especially for women around age 60.
    • Consideration of reimbursement policies and limitations in treating menopausal symptoms is crucial for optimal patient selection.